TriSalus Life Sciences Inc
NASDAQ:TLSI
TriSalus Life Sciences Inc
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
TriSalus Life Sciences Inc is a US-based company operating in industry. The company is headquartered in Westminster, Colorado. The company went IPO on 2020-12-18. TriSalus Life Sciences, Inc. is an oncology company integrating its novel delivery technology with immunotherapy to transform treatment for patients with liver and pancreatic tumors. The Company’s platform includes devices that utilize a drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two FDA-cleared devices use its Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. SD-101, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment. Patient data generated during Pressure-Enabled Regional Immuno-Oncology (PERIO) clinical trials support the hypothesis that SD-101 delivered through PEDD may has favorable immune effects on the liver and systemically.
Revenue: Q4 revenue was $13.2 million and full-year revenue was $45.2 million, representing strong year-over-year growth (60% and 53%, respectively).
Guidance: Management reaffirmed 2026 revenue guidance of $60 million to $62 million, with ~40% of revenue expected in H1 and ~60% in H2 as the expanded commercial team ramps.
Financing: Completed a public offering in February raising $46 million in gross proceeds to fund commercial expansion, clinical studies and product development.
Commercial build: Company is meaningfully doubling its commercial footprint and adding management layers and clinical specialists to accelerate adoption across liver and non-liver indications.
Product roadmap: TriNav Advance expected to clear 510(k) and launch in 1H 2026 (full launch in 2H 2026); TriNav XP and other product launches reported strong early reception.
Clinical programs: Investing in foundational liver studies and multiple registries/trials for thyroid, uterine artery embolization (UAE) and genicular artery embolization (GAE); consolidated nelitolimod PERIO data now expected in 2H 2026.
Profitability trajectory: Q4 adjusted EBITDA loss improved to approximately $950,000; management not providing timing for adjusted EBITDA or cash-flow breakeven yet, prioritizing growth investments.
